Trial reportEuropean journal of nuclear medicine and molecular imaging2011
Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions?
Trial report in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.JAMA · 2014Pooled it
- Non-Invasive Procedure in Differential Diagnosis of Sarcoidosis and Tuberculosis Lymph Nodes: Radiomic Model of 18F-FDG PET-CT.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Distributable, metabolic PET reporting of tuberculosis.Nature communications · 2024Article
- Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers.Frontiers in medicine · 2021Review
- FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.Seminars in nuclear medicine · 2020Review
- Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (Diagnostics (Basel, Switzerland) · 2020Article
- An update on the role ofAmerican journal of nuclear medicine and molecular imaging · 2019Review
- Comparison of the diagnostic performance ofMolecular and clinical oncology · 2015Article
- Methodology for quantitative rapid multi-tracer PET tumor characterizations.Theranostics · 2013Review
- Single-scan dual-tracer FLT+FDG PET tumor characterization.Physics in medicine and biology · 2013Article
- Dual tracer imaging of SPECT and PET probes in living mice using a sequential protocol.American journal of nuclear medicine and molecular imaging · 2012Article
- PET/CT imaging ofClinical and translational imagingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDual-tracer, (18)F-fluorodeoxyglucose and (18)F-fluorodeoxythymidine ((18)F-FDG/(18)F-FLT), dual-modality (positron emission tomography and computed tomography, PET/CT) imaging was used in a clinical trial on differentiation of pulmonary nodules. The aims of this trial were to investigate if multimodality imaging is of advantage and to what extent it could benefit the patients in real clinical settings.
methodsSeventy-three subjects in whom it was difficult to establish the diagnosis and determine management of their pulmonary lesions were prospectively enrolled in this clinical trial. All subjects underwent (18)F-FDG and (18)F-FLT PET/CT imaging sequentially. The images were interpreted with different strategies as either individual or combined modalities. The pathological or clinical evidence during a follow-up period of more than 22 months served as the standard of truth. The diagnostic performance of each interpretation and their impact on clinical decision making was investigated.
results(18)F-FLT/(18)F-FDG PET/CT was proven to be of clinical value in improving the diagnostic confidence in 28 lung tumours, 18 tuberculoses and 27 other benign lesions. The ratio between maximum standardized uptake values of (18)F-FLT and (18)F-FDG was found to be of great potential in separating the three subgroups of patients. The advantage could only be obtained with the full use of the multimodality interpretation. Multimodality imaging induced substantial change in clinical management in 31.5% of the study subjects and partial change in another 12.3%.
conclusionMultimodality imaging using (18)F-FDG/(18)F-FLT PET/CT provided the best diagnostic efficacy and the opportunity for better management in this group of clinically challenging patients with pulmonary lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.